Evidence map›Paper›PMID 36291841›Full record

ArticleCancers2022

Polyethylenimine, an Autophagy-Inducing Platinum-Carbene-Based Drug Carrier with Potent Toxicity towards Glioblastoma Cancer Stem Cells.

Conor McCartin, Candice Dussouillez, Chloé Bernhard, Eric Mathieu, Juliette Blumberger, Monique Dontenwill, Christel Herold-Mende, Ahmed Idbaih, Philippe Lavalle, Stéphane Bellemin-Laponnaz and 2 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Conor McCartin3Bio Team, CAMB UMR7199 CNRS, Faculté de Pharmacie, University of Strasbourg, 67401 Ilkirch, France.ORCID 0000-0003-0259-3623
Candice Dussouillez3Bio Team, CAMB UMR7199 CNRS, Faculté de Pharmacie, University of Strasbourg, 67401 Ilkirch, France.
Chloé BernhardLaboratoire de Bioimagerie et Pathologies UMR CNRS 7021 (LBP), Faculté de Pharmacie, University of Strasbourg, 67401 Illkirch, France.
Eric MathieuInstitut National de la Santé et de la Recherche Médicale, Inserm UMR_S 1121 Biomaterials and Bioengineering, 67085 Strasbourg, France.
Juliette Blumberger3Bio Team, CAMB UMR7199 CNRS, Faculté de Pharmacie, University of Strasbourg, 67401 Ilkirch, France.
Monique DontenwillLaboratoire de Bioimagerie et Pathologies UMR CNRS 7021 (LBP), Faculté de Pharmacie, University of Strasbourg, 67401 Illkirch, France.ORCID 0000-0002-5235-3014
Christel Herold-MendeDivision of Neurosurgical Research, Department of Neurosurgery, University of Heidelberg, 69117 Heidelberg, Germany.ORCID 0000-0002-1915-745X
Ahmed IdbaihAP-HP, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne University, 75013 Paris, France.ORCID 0000-0001-5290-1204
Philippe LavalleInstitut National de la Santé et de la Recherche Médicale, Inserm UMR_S 1121 Biomaterials and Bioengineering, 67085 Strasbourg, France.
Stéphane Bellemin-LaponnazInstitut de Physique et Chimie des Matériaux de Strasbourg (IPCMS) UMR7504 CNRS, University of Strasbourg, 67034 Strasbourg, France.ORCID 0000-0001-9462-5703
Antoine Kichler3Bio Team, CAMB UMR7199 CNRS, Faculté de Pharmacie, University of Strasbourg, 67401 Ilkirch, France.ORCID 0000-0003-0593-2424
Sylvie Fournel3Bio Team, CAMB UMR7199 CNRS, Faculté de Pharmacie, University of Strasbourg, 67401 Ilkirch, France.ORCID 0000-0003-3583-6548

Funding

Fondation ARC pour la Recherche sur le Cancer ARCPJA32020060002306ITI InnoVec Idex ANR-10-IDEX-0002ITI InnoVec SFRI ANR-20-SFRI-0012
6 · The paper itself

Abstract

The difficulty involved in the treatment of many tumours due to their recurrence and resistance to chemotherapy is tightly linked to the presence of cancer stem cells (CSCs). This CSC sub-population is distinct from the majority of cancer cells of the tumour bulk. Indeed, CSCs have increased mitochondrial mass that has been linked to increased sensitivity to mitochondrial targeting compounds. Thus, a platinum-based polyethylenimine (PEI) polymer-drug conjugate (PDC) was assessed as a potential anti-CSC therapeutic since it has previously displayed mitochondrial accumulation. Our results show that CSCs have increased specific sensitivity to the PEI carrier and to the PDC. The mechanism of cell death seems to be necrotic in nature, with an absence of apoptotic markers. Cell death is accompanied by the induction of a protective autophagy. The interference in the balance of this pathway, which is highly important for CSCs, may be responsible for a partial reversion of the stem-like phenotype observed with prolonged PEI and PDC treatment. Several markers also indicate the cell death mode to be capable of inducing an anti-cancer immune response. This study thus indicates the potential therapeutic perspectives of polycations against CSCs.

Indexed as

autophagycancer stem cellsglioblastomaN-heterocyclic carbeneplatinumpolyethyleniminepolymer–drug conjugate

Identifiers

PMID36291841
PMCPMC9599868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.